Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Beats Expectations By $0.04 EPS

Oruka Therapeutics (NASDAQ:ORKA) posted its quarterly earnings results on Wednesday. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04, FiscalAI reports.

Oruka Therapeutics Stock Down 2.3%

Shares of ORKA stock traded down $1.47 during trading hours on Wednesday, reaching $63.18. The company had a trading volume of 947,406 shares, compared to its average volume of 2,397,652. Oruka Therapeutics has a 12 month low of $8.91 and a 12 month high of $91.00. The business has a fifty day simple moving average of $54.01 and a 200-day simple moving average of $38.92.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total transaction of $462,840.00. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,765 shares of company stock valued at $1,089,745 in the last quarter. 23.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $432,000. Janus Henderson Group PLC bought a new stake in Oruka Therapeutics during the fourth quarter worth $367,000. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics in the fourth quarter worth $330,000. Rhumbline Advisers bought a new position in Oruka Therapeutics in the 2nd quarter valued at $320,000. Finally, Police & Firemen s Retirement System of New Jersey increased its position in shares of Oruka Therapeutics by 38.7% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 10,207 shares of the company’s stock valued at $309,000 after purchasing an additional 2,849 shares during the last quarter. 56.44% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ORKA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. BTIG Research lifted their price target on shares of Oruka Therapeutics from $78.00 to $151.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Stifel Nicolaus boosted their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. UBS Group upped their price objective on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Finally, Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $120.80.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.